Orega Biotech

Orega Biotech is a private, preclinical to clinical-stage biotech focused on discovering and developing novel immunotherapies for cancer. The company leverages deep academic roots in immunology to identify and validate new targets, such as CD39, which regulates the immunosuppressive adenosine pathway in the tumor microenvironment. Its asset-centric strategy relies on early partnerships for development and commercialization, evidenced by significant licensing deals with Innate Pharma/AstraZeneca and Genmab. While pre-revenue, its partnered lead asset provides validation and de-risks its pipeline approach.

Target discovery and validation platform focused on identifying novel immune checkpoints and regulators in the tumor microenvironment, leading to first-in-class monoclonal antibody therapies.

Orega competes in the novel immuno-oncology checkpoint space, specifically within the adenosine pathway targeting CD39. It faces competition from companies developing therapies against other adenosine pathway targets (CD73, A2AR) and from other biotechs pursuing CD39 inhibition. Its differentiation lies in its foundational academic discovery of CD39's role and its partnership-driven model.